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ABSTRACT 
Chronic obstructive pulmonary disease (COPD) is a multisystem disease, which resembles 
the accumulation of multiple impairments seen in aging. A Comprehensive Geriatric 
Assessment (CGA) captures multisystem deficits, from which a frailty index (FI) can be 
derived. We hypothesised that patients with COPD would be frailer than a comparator group 
free from respiratory disease. 
 
In this cross-sectional analysis, the CGA questionnaire was completed and used to derive an 
FI in 520 patients diagnosed with COPD and 150 comparators. All subjects were assessed 
for lung function, body composition, 6 minute walking distance (6MWD) and handgrip 
strength. Patients completed validated questionnaires on health related quality of life and 
respiratory symptoms.  
 
Patients and comparators were similar in age, gender and BMI but patients had a greater 
mean±SD FI 0.16±0.08 than comparators 0.05±0.03. In patients, a stepwise linear regression 
6MWD (β=-0.43), number of comorbidities (β= -0.38), handgrip (β= -0.11) and number of 
exacerbations (β= 0.11) were predictors of frailty (all p<0.01). 
 
This large study suggests patients with COPD are frailer than comparators. The FI derived 
from the CGA captures the deterioration of multiple systems in COPD, and provides an 
overview of impairments which may identify individuals at increased risk of morbidity and 
mortality in COPD. 
  
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is one of the few major chronic conditions 
increasing in prevalence. The defining feature of COPD is impaired lung function, but extra-
pulmonary comorbidities contribute to reduced health related quality of life (HRQoL), 
increased morbidity and mortality risk.1, 2 Quantifying multimorbidity is challenging as current 
routine clinical assessments do not take account of comorbidities. However, a scoring 
system based on BMI, airflow obstruction, dyspnoea and exercise (BODE index) and 
comorbidities predicted mortality risk over a four year period.1   
 
Comorbidities represent deficits in individual physiological systems and resemble the 
accumulation of deficits in natural aging, which may result in frailty.3, 4  Frailty is associated 
with aging and manifests as failure to respond to external stresses and maintain 
homeostasis.5 Frailty better predicts adverse outcomes than age, independent of co-existing 
medical conditions.6 The similarities between the accumulation of deficits in aging and 
multiple comorbidities in COPD, suggests that frailty is likely to occur in COPD, and be 
related to increased morbidity.3 Studies in a range of general populations and COPD 
patients have produced an inconsistent prevalence of frailty in COPD 7, 8 ranging from 10% 
frail and 51% intermediate frail, in the Rotterdam study 9 to 57.8% frail in physician 
diagnosed COPD,10 and 25.6% in patients referred for pulmonary rehabilitation.8 A recent 
study reported 21% frailty in a Japanese COPD cohort.11 In addition to various populations 
studied, there were differences in study design, methods to assess frailty and lack of 
appropriate population controls.12, 13  
 
There are a number of validated tools to assess frailty.3, 12, 13 The key ones in current use 
include: 1) the phenotypic definition based on the presence of  ≥ 3 of 5 deficits including; 
walking speed, handgrip strength, activity levels, weight loss and exhaustion,3 which has  
been criticised for not grading or specifying degrees of frailty. 2) To consider frailty as a 
multidimensional, risk state quantified by the number, rather than the nature of physiological 
deficits.3, 6, 13 Using a widely validated questionnaire to capture information on health status 
and function, the Comprehensive Geriatric Assessment (CGA), a frailty Index (FI- CGA) can 
be derived.14 In many populations this operationalised approach to defining and quantifying 
frailty has demonstrated that accumulated deficits, are a stronger predictor of mortality than 
chronological age.13 In geriatric medicine, the FI- CGA is used clinically to assess the 
multisystem impacts of aging and indicate premature aging.6, 14  
 
Although there have been other studies of frailty in COPD, to our knowledge, this is the first 
to explore and report frailty using the CGA, in a well-characterised population of community 
dwelling patients with COPD, along with a group of comparators similar in age and sex from 
the same community. We hypothesised that frailty occurs in COPD based on the FI-CGA 
assessment, and that patients would be more frail than comparators independent of age 
which may indicate an accelerated and premature aging process in COPD.   
 
METHODS 
Study design and participants 
This cross-sectional analysis included community-based patients with COPD, confirmed by 
spirometry at entry, and comparators (current or ex-smokers free from respiratory disease). 
Participants were drawn from the prospective Assessment of Risk in Chronic Airways 
Disease Evaluation (ARCADE) study, (Clinical Trials.gov, NCT01656421)15 and included all 
participants who completed the CGA. All participants were clinically stable, not having 
received or oral corticosteroids in the previous 4 weeks prior to recruitment. Exclusions 
included inflammatory disease such as rheumatoid arthritis, oral maintenance 
corticosteroids, inflammatory bowel syndrome and long-term oxygen therapy. The 
exclusions were to study a sample of patients representative of the general COPD 
population, without significant impairment due to recent exacerbation or use of LTOT.  
 
Participants were recruited from respiratory outpatient clinics, pulmonary rehabilitation, 
smoking cessation referrals, general practice databases and previous participants in 
respiratory research at Cardiff University. Comparators were recruited, based on being a 
current or past smoker, from primary and smoking cessation clinics, as well as past 
volunteers in research and partners of patients with COPD, in an attempt to standardise 
socioeconomic differences. All participants gave written informed consent and the study had 
approval from the South East Wales Research Ethics Committee.  
 
Frailty and questionnaires relating to COPD 
All participants completed a modified version of the CGA questionnaire,4 specific to community 
dwelling individuals was administered to all participants. The CGA collects data on self-rated 
health, psychological wellbeing, mobility, function, nutritional status, medications and co-
morbidities which are coded to reflect deficits (Supplement 1). In community-dwelling 
participants of the Canadian Study of Health and Ageing, the FI-CGA was a valid and reliable 
means of quantifying health status, stratifying patients’ risk of institutionalisation and death.16 
The CGA was modified by removal of the components specific to hospital admission and data 
was collected by a researcher-administered questionnaire, which took less than 10 minutes to 
complete. The FI-CGA was calculated by dividing the total number of CGA deficits by the 
maximum possible score of 61.  
  
Patients with COPD completed the St. George’s Respiratory Questionnaire (SGRQ) a 
validated disease specific measure of HRQoL, scores ranging from 0 to 100, with high scores 
representing worse status,17 and the COPD Assessment Test (CAT), scored 0-40 with high 
scores indicating more symptoms.18 Patients reported the number of respiratory exacerbations 
(defined as requirement for antibiotic or oral corticosteroid therapy) per year19 and the number 
of previously diagnosed comorbidities in patients and comparators were also self-reported 
using a standardised questionnaire which was verified by researcher at the clinical 
assessment. Infrequent exacerbators were defined as <2 in the previous year, while frequent 
exacerbators as ≥2. Breathlessness was recorded using the modified Medical Research 
Council (mMRC) dyspnoea scale. 
 
Lung function 
All participants performed spirometry (Vitalograph Alpha), to determine forced expiratory 
volume in one second (FEV1), forced vital capacity (FVC) and the FEV1:FVC ratio. A 
diagnosis of COPD was confirmed as post bronchodilator spirometry FEV1:FVC <0.70.19 
Patients were classified according to the combined assessment, GOLD A-D based on the 
CAT score.19  
 
Body composition and physical performance   
Weight and body composition were measured barefoot in lightweight indoor clothing, fat 
percentage, fat free mass (Go,  #79) and the body mass index (BMI kg/m2) were determined 
using a segmental bio-electrical impedance analyser (BC418 Tanita Corp, Tokyo). The FFM 
index was expressed as a height-squared ratio (FFMI) kg/m2. A stretch resistant tape 
measure was used to measure waist and hip circumference. 
 
All participants completed the six minute walking distance (6MWD) test with pre-test resting 
heart rate and oxygen saturation by pulse oximetry.20 Mean maximum handgrip strength, 
twice with each hand, was determined using a hand dynamometer (Takei, Japan). 
 
Inflammation 
High sensitivity C-Reactive Protein (HsCRP) and fibrinogen were determined in venous 
blood by standard procedures (University Hospital of Wales, Biochemistry). 
 
 
Data Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences (SPSS, 
Chicago, USA), version 18.0. Results are presented as mean ± standard deviation (SD), 
geometric mean for log10 transformed data and median, interquartile range [IQR]. Analyses 
included the independent t-test, Wilcoxon test, Pearson’s (r) or Spearman’s (rs) correlation, 
and stepwise multiple regression. 
 
 
 
 
RESULTS 
 
Participant characteristics 
The FI was greater in the patients 0.16 ±0.08 than the comparators 0.05 ±0.03, (p<0.001). 
Patients also had poorer lung function FEV1, FVC and FEV1/FVC, greater smoking history, 
larger waist circumference, lower handgrip and 6MWD, as well as greater inflammation 
(HsCRPlog10 and fibrinogen). However, patients and comparators were similar in age, 
gender, BMI and body composition (Table 1).  
Female patients had greater FI 0.17 ±0.09, than males 0.14 ±0.09, (p<0.001) and female 
comparators had greater FI 0.06 ±0.04 than males 0.04 ±0.03. 
 
Frailty and characteristics of COPD 
Based on the upper 90th centile FI for comparators (0.09) as a cut-off for frailty, 76% of the 
patients were frail and 13% of comparators were frail. However, using the upper 50% CI of 
the age adjusted cut-off for frailty from the SHARE cohort (a large general, unselected, age 
related European population) 28% (n=143) of patients and 0% of comparators were frail. 
Frail patients (according to SHARE) were younger, had poorer lung function, greater BMI, 
waist and fat percentage as well as poorer handgrip and 6MWD compared to non-frail 
patients. Frail patients also had greater inflammation (IL-6 and HsCRP) and more 
exacerbations, symptoms (CAT) and poorer quality (SGRQ) all p<0.05 (Table 1). 
 
Medical History 
Patients with COPD had more comorbidities and reported more medications than 
comparators (p<0.05). The most commonly reported comorbidity in both patients and 
comparators was hypertension and hypercholesterolaemia.  
Frail patients with COPD had more comorbidities including a greater proportion reporting 
cardiovascular disorders as well as diabetes, osteoporosis and osteoarthritis and more 
medications than non-frail patients with COPD (p<0.05) (Table 2). This remained after 
adjustment of age and the number of comorbidities: frail 0.18 ±0.05 versus non-frail 0.14 
±0.4 (p<0.05). Of the patients, frequent exacerbators (>2/year) n=310, had a greater mean 
FI 0.19 ±0.09 than infrequent exacerbations, (0-1/year) n=210, 0.15 ±0.08, and both had a 
greater FI than that of the comparator group’, 0.05 ±0.04 (p<0.001).  
 
Using the SHARE cut-off for frailty for each decade,21 mean FI and the percentage of frail 
patients differed across: age categories (Figure 1a),  MRC dyspnoea (Figure 1b),  GOLD 1-4 
(Figure 1c), and classified according to the Gold 1-4 and using the combined assessment of 
COPD A-D using the CAT score (Figure 1d) (all p<0.05). Age and gender did not differ 
across the classifications and only the number of comorbidities differed across the gold 
categories A-D. 
When adjusted statistically for the number of comorbidities, the number of patients classified 
as frail according to SHARE reduced to n=75. The proportion of frail patients no longer 
differed across the mMRC, Gold1-4 or Gold A-D categories (p>0.05). 
 
Relationships between Frailty Index and Participant Characteristics 
In COPD, FI was inversely related to FEV1%, handgrip and 6MWD. Measures of body 
composition (BMI, waist circumference and fat percentage) and inflammation (HsCRP and 
fibrinogen) were directly related to FI, along with disease specific questionnaires as well as 
the number of comorbidities and exacerbations per year (all p<0.01)(Table 3).  
In patients, a stepwise linear regression with the FI as a dependent variable, FEV1%, BMI, 
handgrip, 6MWD, number of exacerbations per year, number of comorbidities and 
fibrinogenlog10, as were  included as independent variables, based on the results of 
correlations between CGA and the independent variables. This produced a significant model 
which explained 51% of the variance of frailty. 6MWD (β=-0.43), was the primary predictor, 
followed by number of comorbidities (β= -0.38), handgrip (β= -0.11) and number of 
exacerbations (β= 0.11) (all p<0.01). In comparators, number of comorbidities (β=-0.432), 
6MWD (β=-2.33) and BMI (β= 0.22) explained 38% of the variance of frailty (p<0.01). 
In frail patients, the FI was related to BMI (r=0.12), fat mass (r=0.13), waist (r=0.24), HGS 
(r=-0.26), 6MWD (r=-0.46), number of exacerbations (rs=0.14), SGRQ (rs=0.48) and CAT 
(rs=0.45) (all p<0.05), but not inflammation.  
 DISCUSSION  
In this study, patients with COPD were frailer than a comparator group, similar in age, 
gender and BMI but free from respiratory disease, and as demonstrated by their greater 
number of deficits measured as part of the CGA and higher FI score. In our female patients 
and comparators, the FI was greater than in their counterpart males, a similar relationship to 
that reported in the general population. The mean FI of females with COPD was greater than 
the reported FI of 0.15 for women over 65 years of age from general populations.22-24  
 
The finding that 28% of our patients were frail based on the SHARE cohort is similar to a 
recent UK study in patients referred for pulmonary rehabilitation which reported that 26% of 
their patients were frail using a hybrid of Fried’s criteria.8 A recent study reported a 
prevalence of 21% frailty in patients with COPD using the Kihon Checklist.11 These studies 
are lower than a UK population study where the reported prevalence of frailty was 57.8% in 
70 COPD patients diagnosed on the basis of symptoms rather an objective measure of 
airways obstruction.10 Unlike the latter study, our study population was unselected based on 
physician defined COPD with mandatory demonstration of airways obstruction at the time of 
entry to the ARCADE study15 and hence provided a wider spectrum of disease severity and 
comorbidities which might account for the variation. Comparisons between this study and 
other studies7, 25 are difficult due to different assessments of frailty and older study 
populations, which may not represent a typical COPD population. We used the validated 
CGA tool, which allowed our participants to be compared with other populations and has 
shown to be a predictor of outcomes than chronological age, disability and the need for 
healthcare support.6, 13 Based on our own cut-off from frailty from our comparator group the 
percentage of frail patients was high (76%). This may be a result of low levels of frailty in 
comparators due to rigorous exclusion criteria and self-selection of volunteers for the study.   
 
Using the SHARE cut-off frail patients had reduced physical capacity, greater systemic 
inflammation, worse symptoms and quality of life. Hence, frailty in COPD appears to have 
impacts and background mechanisms similar to those in natural aging where it is part of the 
spectrum of multimorbidity. There is likely to be two aspects of COPD interwoven with each 
other and frailty; the physiological processes of natural aging occurring in all individuals and 
the impact of COPD and its associated exacerbations and greater comorbidity levels.26 
Comorbidities in COPD are an important factor in the overall morbidity and mortality 1 and 
their interaction may be related to the greater systemic inflammatory state in aging – 
inflammaging – and the inflammatory surges during exacerbations superimposed on the 
background inflammatory state in COPD.27  This speculation is supported by the association 
between frailty and the number of comorbidities and number of exacerbations per year seen 
in this study. This potentially provides a testable explanation of premature aging in COPD.  
 
Although, frailty in COPD was unrelated to chronological age, the proportion of frail patients 
differed across the age categories. Interestingly, patients aged 50-59 had greatest FI and the 
largest proportion of frail patients which could potentially be explained by a survival bias 
where frail patients fail to reach older age. In addition, frailty differed according to the 
disease severity classified by GOLD, in mild disease (Gold 1) 17% of patients were frail 
increasing to 34% frail in Gold 3 and 4. Patients in GOLD categories B&D with more 
symptoms as measured by the CAT score were frailer. These differences did not remain 
when frailty was adjusted for the number of comorbidities. This suggests that frailty may be 
as a result of increasing deficits which may occur prematurely even in mild COPD.  
 
Frailty associated with components of body composition, including BMI, fat% and waist 
circumference. The linear relationship with BMI contrasts with the U-shaped distribution 
reported in the English Longitudinal Study of Ageing, but may be a consequence of small 
numbers of individuals with a low BMI.22 In both COPD and natural aging, increases in fat 
and abdominal obesity have been closely linked to impaired physical function.28 Increased 
fat mass and frailty in the older people has also been linked to increased levels of circulating 
inflammatory biomarkers.29 Circulating CRP, an indicator of IL-6 activity, increases with age 
and has been linked to frailty and truncal obesity, independent of BMI, which may reflect the 
negative impact of chronic low grade systemic inflammation, a feature of COPD, on physical 
function and wellbeing.30 Hence, our findings suggest frailty in COPD is a multifactorial 
function perhaps resulting in reduced physical function and quality of life. 
 
In the present study frailty was predicted by physical function (6MWD and handgrip) and the 
number of exacerbations and co-morbidities. This aligns with previous studies where the 
non-linear association of frailty with age, functional dependence, and chronic disease has 
been established.3, 4, 6, 12-14, 31 Although there are few specific studies in individual chronic 
diseases, such as reported here, in the Women’s Health and Aging Studies, the risk of frailty 
increased with inflammatory comorbidities. This showed that the combination of pulmonary 
disease with anaemia carried a risk ratio of 5.57 compared with comparator participants who 
had fewer comorbidities.32 A further study in this female cohort demonstrated that frailty was 
related non-linearly to the number of abnormal physiological systems, which resembles the 
impact of multiple comorbidities in COPD.12 Such physiological deficits included loss of 
skeletal muscle mass (sarcopenia) and function, with progressive loss of capacity for 
physical activity, loss of bone mineral density, increased systemic inflammation, reduction in 
HRQoL and increasing cardiovascular morbidity and mortality.22, 33, 34  
 
Our patients with COPD were stable at the time of recruitment but had higher levels of 
inflammation (HsCRP and fibrinogen) than comparators, however the difference in fibrinogen 
between patients and comparators was small. The higher, than expected, levels of 
inflammation in comparators may be attributed to the age of the participants and potential 
presence of subclinical disease in some comparators despite being free from occult 
respiratory, cardiovascular disease or inflammatory conditions.35 COPD is characterised by 
low-grade inflammation, both CRP and fibrinogen are acute phase proteins produced by the 
liver and have been associated with disease severity in COPD. However, fibrinogen is 
thought to be a more specific marker and has being associated with increased risk of 
exacerbation, hospitalisation and extra pulmonary manifestations.36 The reported 
associations with frailty and aging, in many ways parallels findings in COPD, where systemic 
inflammation may be causal, compensatory or an epi-phenomenon.  
 
This accumulation of deficits in COPD resembled the pattern of that occurring with aging 
healthy populations, potentially allowing the prediction of poor outcomes such as increased 
risk of falls, hospitalisation, residential care, reduced HRQoL, disability and increased 
mortality.3, 4, 6, 12-14, 31 Although there are a number of ways of determining frailty, the CGA 
has the advantage of being a simple, rapid questionnaire that is applicable for all healthcare 
sectors. 
 
Limitations of the study 
As with the majority of cross-sectional studies a limitation of the findings is that they may be 
influenced by bias, confounding and lack of causality. Although patients and comparators 
were similar they were not matched and there were differences the number of comorbidities 
between the groups. This, however, reflects the multisystem nature of the COPD, which is 
inherent to the disease. The ARCADE study was designed to describe a representative 
COPD group and a comparator group rather than a true controlled study. Frailty did not 
relate to age and after adjustment for smoking history, frailty remained elevated in COPD in 
line with Park’s study where smoking was unrelated to frailty.10 A limitation of the CGA 
questionnaire to determine frailty is that it relies on patient recall, nevertheless, many of the 
parameters could be verified by medical notes, physical assessment and carers. 
 
 
CONCLUSION 
Patients with COPD were frailer than a comparator group of current or ex-smokers, 
independent of age. Frailty was predicted by the number of comorbidities and the number of 
exacerbations per year as well as physical function. This study highlights the need to take a 
holistic view of COPD to quantify the systemic nature of the disease. The CGA is a quick, 
simple and inexpensive questionnaire that provides a global assessment of COPD. The 
CGA may be a useful clinical tool to highlight the multisystem deficits of COPD, which could 
guide interventions, monitor disease processes and improve patient care.  
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